Tearsheet

Bio Green Med Solution (BGMS)

Market Price (5/22/2026): $1.02 | Market Cap: $5.6 Mil
Sector: Health Care | Industry: Biotechnology

Bio Green Med Solution (BGMS)

Market Price (5/22/2026): $1.02
Market Cap: $5.6 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -62%

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 10793%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -67%

Megatrend and thematic drivers
Megatrends include Health & Wellness Trends, and Biotechnology & Genomics. Themes include Nutritional Supplements, Organic & Natural Products, Show more.

Weak multi-year price returns
2Y Excs Rtn is -122%, 3Y Excs Rtn is -162%

Penny stock
Mkt Price is 1.0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -3.6 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -238%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 44%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -118%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -118%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -62%

High stock price volatility
Vol 12M is 113%

Key risks
BGMS key risks include [1] a material going-concern risk due to its dire financial instability, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -62%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 10793%
2	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -67%
3	Megatrend and thematic drivers Megatrends include Health & Wellness Trends, and Biotechnology & Genomics. Themes include Nutritional Supplements, Organic & Natural Products, Show more.
4	Weak multi-year price returns 2Y Excs Rtn is -122%, 3Y Excs Rtn is -162%
5	Penny stock Mkt Price is 1.0
6	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -3.6 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -238%
7	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 44%
8	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -118%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -118%
9	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -62%
10	High stock price volatility Vol 12M is 113%
11	Key risks BGMS key risks include [1] a material going-concern risk due to its dire financial instability, Show more.

Valuation, Metrics & Events

	5/22/26	2025	2024	2023	2022
Share Price CYE	$1.02	$1.48	�	�	�
Market Cap CYE ($ Mil)	5.6	8.0	-	-	-
Total Debt ($ Mil)	0.0	0.0	0.0	0.0	0.1
Total Cash ($ Mil)	3.3	3.5	3.1	3.4	18.3
Enterprise Value ($ Mil)	2.2	8.0
Valuation Ratios
P/S TTM	3.7	10.7	-	-	-
P/EBIT TTM	-1.5	-1.1	-	-	-
P/E TTM	-1.8	-2.7	-	-	-
P/FCF TTM	-3.1	-1.7	-	-	-
Sector Ratios
P/S TTM (Sector)	3.8	4.3	3.8	4.2	4.5
P/EBIT TTM (Sector)	-1.8	-1.7	-1.5	-1.5	-1.3
P/E TTM (Sector)	-1.9	-1.9	-1.7	-1.6	-1.3
P/FCF TTM (Sector)	-1.9	-1.8	-1.5	-1.4	-1.6

	5/22/26	2025	2024
Share Price CYE	$1.02	$1.48	�
Market Cap CYE ($ Mil)	5.6	8.0	-
Total Debt ($ Mil)	0.0	0.0	0.0
Total Cash ($ Mil)	3.3	3.5	3.1
Enterprise Value ($ Mil)	2.2	8.0
Valuation Ratios
P/S TTM	3.7	10.7	-
P/EBIT TTM	-1.5	-1.1	-
P/E TTM	-1.8	-2.7	-
P/FCF TTM	-3.1	-1.7	-
Sector Ratios
P/S TTM (Sector)	3.8	4.3	3.8
P/EBIT TTM (Sector)	-1.8	-1.7	-1.5
P/E TTM (Sector)	-1.9	-1.9	-1.7
P/FCF TTM (Sector)	-1.9	-1.8	-1.5

	BGMS	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.0
Rev Chg Q	�	8.7%
Rev Chg LTM	10,792.9%	7.4%
Rev Chg 3Y Avg	5,348.0%	5.8%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-238.5%	18.4%
CFO/Rev LTM	-118.1%	21.1%
Net Inc Mgn	-204.2%	13.0%
VALUATION	MODERATE
P/S	3.7	3.2
P/CFO	-3.1	15.0
P/FCF	-3.1	19.2
P/E	-1.8	23.4
STABILITY	VERY GOOD
Debt/Equity	0.00	0.22
Cash/Assets	0.44	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Employee Count	12	12302024	Link

Recent
5/15/2026	Earnings Release	Rev: $0.0 Mil (A) vs. $null (E) EPS: -0.04 (A) vs. $- (E)

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Bio Green Med Solution (BGMS) stock has lost about 20% since 1/31/2026 because of the following key factors:

1. "Going Concern" Warning and Weak Financial Position. Bio Green Med Solution's management explicitly stated "substantial doubt" about the company's ability to continue as a going concern for at least twelve months without securing new financing or engaging in a strategic transaction. For the first quarter of 2026, the company reported a net loss of $0.2 million, an increase from a $0.1 million loss in the prior-year period. Additionally, cash and cash equivalents decreased from $3.5 million at December 31, 2025, to $3.3 million at March 31, 2026.

2. Delisting of Preferred Stock. In March 2026, the company's 6% Convertible Exchangeable Preferred Stock (BGMSP) was delisted from the Nasdaq Capital Market. This action was a result of the company failing to meet Nasdaq's minimum market value of publicly held shares requirement. While the delisting did not affect the common stock (BGMS), it signaled financial instability and likely contributed to a decline in investor confidence.

Show more

Holding a concentrated position? Know your true downside before the momentum shifts.

Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -18.5% change in BGMS stock from 1/31/2026 to 5/21/2026 was primarily driven by a -87.6% change in the company's P/S Multiple.

(LTM values as of)	1312026	5212026	Change
Stock Price ($)	1.21	0.99	-18.5%
Change Contribution By:
Total Revenues ($ Mil)	0	2	1782.7%
P/S Multiple	28.6	3.5	-87.6%
Shares Outstanding (Mil)	2	5	-65.0%
Cumulative Contribution			-18.5%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2026 to 5/21/2026

	Return	Correlation
BGMS	-18.5%
Market (SPY)	7.6%	30.3%
Sector (XLV)	-3.9%	20.1%

Fundamental Drivers

The -44.6% change in BGMS stock from 10/31/2025 to 5/21/2026 was primarily driven by a -98.7% change in the company's P/S Multiple.

(LTM values as of)	10312025	5212026	Change
Stock Price ($)	1.78	0.99	-44.6%
Change Contribution By:
Total Revenues ($ Mil)	0	2	15150.0%
P/S Multiple	281.9	3.5	-98.7%
Shares Outstanding (Mil)	2	5	-71.0%
Cumulative Contribution			-44.6%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 5/21/2026

	Return	Correlation
BGMS	-44.6%
Market (SPY)	9.5%	28.2%
Sector (XLV)	3.6%	7.2%

Fundamental Drivers

null
null

Market Drivers

4/30/2025 to 5/21/2026

	Return	Correlation
BGMS
Market (SPY)	35.5%	23.1%
Sector (XLV)	7.3%	5.5%

Fundamental Drivers

null
null

Market Drivers

4/30/2023 to 5/21/2026

	Return	Correlation
BGMS
Market (SPY)	85.6%	23.1%
Sector (XLV)	16.6%	5.5%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
BGMS Return	-	-	-	-	-72%	-35%	-82%
Peers Return	-7%	32%	41%	-1%	2%	0%	74%
S&P 500 Return	27%	-19%	24%	23%	16%	9%	98%
Monthly Win Rates [3]
BGMS Win Rate	-	-	-	-	0%	20%
Peers Win Rate	42%	67%	58%	50%	67%	36%
S&P 500 Win Rate	75%	42%	67%	75%	67%	60%
Max Drawdowns [4]
BGMS Max Drawdown	-	-	-	-	-	-48%
Peers Max Drawdown	-27%	-19%	-12%	-23%	-29%	-28%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ALPS, AVLN, COAG, DFTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/21/2026 (YTD)

BGMS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Event	XLV	S&P 500
2025 US Tariff Shock
% Loss	-11.7%	-18.8%
% Gain to Breakeven	13.3%	23.1%
Time to Breakeven	142 days	79 days
2022 Inflation Shock & Fed Tightening
% Loss	-13.8%	-24.5%
% Gain to Breakeven	15.9%	32.4%
Time to Breakeven	166 days	427 days
2020 COVID-19 Crash
% Loss	-27.9%	-33.7%
% Gain to Breakeven	38.8%	50.9%
Time to Breakeven	77 days	140 days
Q4 2018 Fed Policy Error / Growth Scare
% Loss	-15.0%	-19.2%
% Gain to Breakeven	17.6%	23.8%
Time to Breakeven	191 days	105 days
2015-2016 China Devaluation / Global Growth Scare
% Loss	-15.9%	-12.2%
% Gain to Breakeven	18.9%	13.9%
Time to Breakeven	165 days	62 days
2011 US Debt Ceiling Crisis & European Contagion
% Loss	-15.8%	-17.9%
% Gain to Breakeven	18.8%	21.8%
Time to Breakeven	153 days	123 days

Compare to VRTX, ALPS, AVLN, COAG, DFTX

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

BGMS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Event	XLV	S&P 500
2020 COVID-19 Crash
% Loss	-27.9%	-33.7%
% Gain to Breakeven	38.8%	50.9%
Time to Breakeven	77 days	140 days
2008-2009 Global Financial Crisis
% Loss	-37.9%	-53.4%
% Gain to Breakeven	61.1%	114.4%
Time to Breakeven	767 days	1085 days

Compare to VRTX, ALPS, AVLN, COAG, DFTX

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Bio Green Med Solution (BGMS)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

AI Analysis | Feedback

A small, early-stage Merck, but purely focused on developing new cancer drugs that are still in clinical trials.

Like a startup biotech aiming to discover the next breakthrough cancer treatment, similar to an early-stage Gilead Sciences.

Moderna, but for oncology drugs that are currently in clinical development, rather than vaccines.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer

Datuk Dr. Doris Wong Sing Ee was elected as the Chief Executive Officer and Executive Director of Bio Green Med Solution (formerly Cyclacel Pharmaceuticals, Inc.) in February 2025 after acquiring a controlling 70% stake in the company. She brings over 20 years of experience in various industries. Since October 2020, she has served as an Executive Director of Metronic Global Bhd, an investment holding company, where she has been responsible for optimizing financial operations, establishing business goals, advising the board of directors on organizational activities, and executing special business projects. Dr. Wong has also been involved in various investment opportunities focused on business diversification, revenue generation, and increasing shareholders' wealth. Prior to her appointment at Cyclacel, she served as an independent director and a member of the audit and compensation committees of Energem Corp from November 2021 until January 2023.

Kiu Cu Seng, Chief Financial Officer

Kiu Cu Seng was appointed as Executive Director, Secretary, and Chief Financial Officer of Bio Green Med Solution (formerly Cyclacel Pharmaceuticals, Inc.) in February 2025. He brings significant accounting and audit experience to the company.

AI Analysis | Feedback

The public company Bio Green Med Solution (symbol: BGMS) faces several key risks, primarily stemming from its nature as a clinical-stage biopharmaceutical company, as described in the provided background information. Here are the key risks:

Clinical Trial and Regulatory Approval Risk: The most significant risk for Bio Green Med Solution, based on the description, is the inherent uncertainty and high failure rate associated with clinical trials and the subsequent regulatory approval process for new drug candidates. The company's development programs, including fadraciclib, CYC140, Sapacitabine, and seliciclib, are all in Phase 1/2 clinical trials or investigator-sponsored trials. There is no guarantee that these drug candidates will demonstrate sufficient efficacy or safety in later-stage trials, or that they will ultimately receive the necessary regulatory approvals from health authorities like the FDA to be commercialized. Failure at any stage of development or inability to obtain approval would severely impact the company's prospects.
Product Pipeline and Development Stage Risk: As a clinical-stage biopharmaceutical company, Bio Green Med Solution, as described, does not currently have any approved commercial products. Its future success and ability to generate revenue are entirely dependent on the successful development, approval, and commercialization of its pipeline candidates. If none of these candidates reach the market, the company would lack a sustainable revenue stream.
Funding and Capital Needs: The research and development of pharmaceutical products, especially through extensive clinical trials, are highly capital-intensive processes. Bio Green Med Solution, as described, requires substantial ongoing funding to advance its various drug development programs. There is a risk that the company may not be able to secure adequate additional financing on favorable terms, or at all, which could lead to delays, curtailment, or even discontinuation of critical research and development efforts.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Capital Allocation Decisions (Bio Green Med Solution, Inc. - BGMS)

Share Issuance

Bio Green Med Solution, Inc. implemented a 1-for-15 reverse stock split on its common stock, effective July 7, 2025, to meet Nasdaq bid price requirements. This action reduced the number of outstanding common shares from 23,759,475 to 1,583,965.
The company executed other reverse stock splits, including a 1-for-15 split on December 18, 2023, and a 1-for-16 split on May 12, 2025.
Bio Green Med Solution entered into multiple Warrant Exchange Agreements where existing warrants to purchase common stock were exchanged for newly issued common shares.

Inbound Investments

Around late 2024/early 2025, there was an investment of $3.1 million in Preferred Stock, concurrently with the appointment of an Interim CEO.

Outbound Investments

In September 2025, Bio Green Med Solution, Inc. completed the acquisition of Fitters Sdn. Bhd., a Malaysia-based company specializing in fire safety and protection solutions, diversifying its business portfolio. As part of this Exchange Transaction, BGMS issued 699,158 shares of its common stock, representing 19.99% of its then-issued and outstanding common stock, in exchange for all of Fitters' equity interests.
On October 6, 2025, the company acquired Assets and Rights of Plogosertib from Tethra Biosciences Inc. for $0.47 million.

Capital Expenditures

Bio Green Med Solution Inc reported $0 in capital expenditures for Q3 2024.
The company also reported $0 in capital expenditures for several quarters, including June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024.

Interactive Breakdown

null

null

Better Bets vs. Bio Green Med Solution (BGMS)

null

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Can Bio Green Med Solution Stock Hold Up When Markets Turn?	10/17/2025

	Title
0	ARTICLES

Trade Ideas

Select ideas related to BGMS.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GEHC_4302026_Dip_Buyer_FCFYield	04302026	GEHC	GE HealthCare Technologies	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
IQV_4302026_Dip_Buyer_FCFYield	04302026	IQV	IQVIA	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
UHS_4302026_Dip_Buyer_FCFYield	04302026	UHS	Universal Health Services	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
ABT_4302026_Dip_Buyer_ValueBuy	04302026	ABT	Abbott Laboratories	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	0.0%	0.0%	0.0%
ZBIO_4302026_Insider_Buying_45D_2Buy_200K	04302026	ZBIO	Zenas BioPharma	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	0.0%	0.0%	0.0%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FBYD	Falcons Beyond Global	0.8	36.6%	27.2%
QBTS	D-Wave Quantum	9.1	33.4%	-1.6%
RGTI	Rigetti Computing	7.3	30.6%	-0.5%
FCEL	FuelCell Energy	1.3	30.5%	260.9%
APLD	Applied Digital	13.5	21.5%	95.8%
QUBT	Quantum Computing	2.5	19.4%	11.2%
WOLF	Wolfspeed	1.9	18.6%	299.2%
HOV	Hovnanian Enterprises	0.7	17.8%	18.4%
ENPH	Enphase Energy	8.2	17.3%	94.5%
AXTI	AXT	5.4	15.7%	640.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
INTU	Intuit	85.4	-20.0%	-53.4%
SLS	SELLAS Life Sciences	1.1	-15.7%	100.5%
BVS	Bioventus	0.6	-13.2%	27.6%
NPK	National Presto Industries	0.9	-10.2%	21.5%
GTN-A	Gray Media	0.9	-9.9%	-28.2%
SATS	EchoStar	37.0	-9.4%	18.2%
BORR	Borr Drilling	1.6	-8.7%	40.0%
NN	NextNav	2.9	-7.8%	28.5%
VAL	Valaris	7.1	-7.4%	101.3%
WMT	Walmart	967.2	-7.3%	9.3%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
FBYD	Falcons Beyond Global	0.8	68.9%	27.2%
TE	T1 Energy	1.9	52.2%	30.5%
RXO	RXO	4.1	39.1%	92.7%
BLDP	Ballard Power Systems	1.6	31.5%	113.8%
SG	Sweetgreen	1.1	30.3%	32.8%
ALAB	Astera Labs	50.5	30.3%	79.0%
RAMP	LiveRamp	2.4	29.9%	28.8%
ENPH	Enphase Energy	8.2	29.8%	94.5%
HIVE	HIVE Digital Technologies	0.9	29.6%	49.2%
SEDG	SolarEdge Technologies	3.8	25.4%	118.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
POET	POET Technologies	1.8	-28.0%	134.1%
DSGN	Design Therapeutics	0.6	-24.3%	17.4%
BTGO	BitGo	0.9	-21.3%	-58.0%
FIGR	Figure Technology Solutions	7.4	-20.5%	-15.8%
USAS	Americas Gold And Silver	1.6	-20.1%	11.7%
OPTU	Optimum Communications	0.3	-18.8%	-56.7%
INTU	Intuit	85.4	-18.8%	-53.4%
GTN-A	Gray Media	0.9	-18.6%	-28.2%
SVM	Silvercorp Metals	2.7	-18.2%	46.6%
ONDS	Ondas	3.5	-18.1%	-5.9%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
MXL	MaxLinear	8.7	194.1%	471.8%
WOLF	Wolfspeed	1.9	150.5%	299.2%
BAND	Bandwidth	1.8	149.0%	278.9%
FCEL	FuelCell Energy	1.3	123.6%	260.9%
INOD	Innodata	3.2	108.2%	93.4%
INTC	Intel	602.3	81.6%	221.1%
VPG	Vishay Precision	1.4	81.5%	170.2%
XMTR	Xometry	4.5	79.6%	46.1%
PENG	Penguin Solutions	2.6	77.0%	149.5%
ENPH	Enphase Energy	8.2	76.3%	94.5%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
CAR	Avis Budget	5.6	-64.5%	22.9%
EMBC	Embecta	0.2	-64.0%	-71.6%
FWRD	Forward Air	0.3	-63.3%	-66.6%
CABO	Cable One	0.3	-58.6%	-57.7%
OPTU	Optimum Communications	0.3	-58.3%	-56.7%
PSIX	Power Solutions International	0.9	-53.1%	-30.7%
TRDA	Entrada Therapeutics	0.3	-51.6%	-38.6%
ERAS	Erasca	3.3	-46.4%	212.0%
BETR	Better Home & Finance	0.4	-45.5%	-23.2%
BRBR	BellRing Brands	1.1	-45.2%	-66.1%

Peer Comparisons

Peers to compare with:

Financials

	BGMS	VRTX	ALPS	AVLN	COAG	DFTX	Median
Name	Bio Gree.	Vertex P.	ALPS	Avalyn P.	Hemab Th.	Definium.
Mkt Price	0.99	433.54	0.70	28.41	26.30	22.65	24.48
Mkt Cap	0.0	110.2	-	-	-	2.5	2.5
Rev LTM	2	12,218	-	-	-	0	2
Op Inc LTM	-4	4,662	-	-	-	-193	-4
FCF LTM	-2	3,710	-	-	-	-145	-2
FCF 3Y Avg	-7	1,977	-	-	-	-101	-7
CFO LTM	-2	4,241	-	-	-	-145	-2
CFO 3Y Avg	-7	2,401	-	-	-	-101	-7

Growth & Margins

	BGMS	VRTX	ALPS	AVLN	COAG	DFTX	Median
Name	Bio Gree.	Vertex P.	ALPS	Avalyn P.	Hemab Th.	Definium.
Rev Chg LTM	10,792.9%	10.1%	-	-	-	-	5,401.5%
Rev Chg 3Y Avg	-	9.9%	-	-	-	-	9.9%
Rev Chg Q	-	7.8%	-	-	-	-	7.8%
QoQ Delta Rev Chg LTM	104.1%	1.8%	-	-	-	-	53.0%
Op Inc Chg LTM	69.3%	1,214.0%	-	-	-	-69.8%	69.3%
Op Inc Chg 3Y Avg	45.8%	364.1%	-	-	-	-42.7%	45.8%
Op Mgn LTM	-238.5%	38.2%	-	-	-	-	-100.2%
Op Mgn 3Y Avg	-29,994.3%	24.1%	-	-	-	-	-14,985.1%
QoQ Delta Op Mgn LTM	779.6%	0.2%	-	-	-	-	389.9%
CFO/Rev LTM	-118.1%	34.7%	-	-	-	-	-41.7%
CFO/Rev 3Y Avg	-26,366.8%	21.5%	-	-	-	-	-13,172.6%
FCF/Rev LTM	-118.2%	30.4%	-	-	-	-	-43.9%
FCF/Rev 3Y Avg	-26,366.8%	17.7%	-	-	-	-	-13,174.5%

Valuation

	BGMS	VRTX	ALPS	AVLN	COAG	DFTX	Median
Name	Bio Gree.	Vertex P.	ALPS	Avalyn P.	Hemab Th.	Definium.
Mkt Cap	0.0	110.2	-	-	-	2.5	2.5
P/S	3.5	9.0	-	-	-	-	6.3
P/Op Inc	-1.5	23.6	-	-	-	-12.7	-1.5
P/EBIT	-1.5	21.8	-	-	-	-10.6	-1.5
P/E	-1.7	25.4	-	-	-	-10.4	-1.7
P/CFO	-3.0	26.0	-	-	-	-17.0	-3.0
Total Yield	-57.6%	3.9%	-	-	-	-9.6%	-9.6%
Dividend Yield	0.0%	0.0%	-	-	-	0.0%	0.0%
FCF Yield 3Y Avg	-	1.8%	-	-	-	-	1.8%
D/E	0.0	0.0	-	-	-	0.0	0.0
Net D/E	-0.6	-0.0	-	-	-	-0.1	-0.1

Returns

	BGMS	VRTX	ALPS	AVLN	COAG	DFTX	Median
Name	Bio Gree.	Vertex P.	ALPS	Avalyn P.	Hemab Th.	Definium.
1M Rtn	-16.5%	-0.7%	-24.7%	-3.7%	-22.6%	-5.0%	-10.7%
3M Rtn	-5.2%	-7.6%	-22.2%	-3.7%	-22.6%	31.2%	-6.4%
6M Rtn	-19.9%	2.7%	-23.1%	-3.7%	-22.6%	67.7%	-11.8%
12M Rtn	-81.2%	-0.4%	-26.3%	-3.7%	-22.6%	67.7%	-13.2%
3Y Rtn	-81.2%	27.5%	-26.3%	-3.7%	-22.6%	67.7%	-13.2%
1M Excs Rtn	-20.8%	-5.3%	-29.8%	-8.0%	-27.0%	-6.2%	-14.4%
3M Excs Rtn	-13.0%	-16.9%	-29.1%	-11.4%	-30.4%	24.5%	-14.9%
6M Excs Rtn	-39.0%	-13.0%	-26.3%	-16.2%	-35.2%	55.1%	-21.2%
12M Excs Rtn	-106.5%	-28.4%	-51.6%	-29.0%	-48.0%	42.3%	-38.5%
3Y Excs Rtn	-162.4%	-55.6%	-107.4%	-84.8%	-103.8%	-13.5%	-94.3%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	3/31/2026	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	5/15/2026	3/30/2026	4/2/2025	3/21/2024	3/8/2023	3/30/2022	3/1/2021
Key Financials
Total Revenue	2	1	0	0	0	0	0
EBITDA	-4	-8	-12	-25	-28	-22	-11
Operating Income	-4	-8	-12	-25	-28	-22	-11
Net Income	-3	-3	-11	-23	-21	-18	-8
EPS	-18.26	-6.45	-502.46	-6419.18	-6888.00	-7524.00	-12312.00
Growth Rates
Total Revenue Growth	10792.9%	1637.2%	-89.8%	∞%	-	-	-
EBITDA Growth	69.5%	29.8%	52.8%	8.0%	-23.6%	-110.5%	-9.9%
Operating Income Growth	69.3%	29.8%	52.8%	8.0%	-23.5%	-110.5%	-9.9%
Net Income Growth	62.7%	73.3%	50.3%	-6.4%	-14.9%	-118.6%	-7.9%
Margins
EBITDA Margin	-238.1%	-1127.4%	-27902.3%	-6052.9%	-	-	-
Operating Income Margin	-238.5%	-1128.1%	-27916.3%	-6060.2%	-	-	-
Net Income Margin	-204.2%	-401.3%	-26074.4%	-5370.2%	-	-	-
Cash & Debt
Total Cash	3	4	3	3	18	37	33
Total Debt	0	0	0	0	0	0	1
Net Debt / (Cash)	-3	-4	-3	-3	-18	-37	-32
Cash Flows
Net Cash from Operations	-2	-5	-8	-16	-21	-19	-8
Free Cash from Operations	-2	-5	-8	-16	-21	-19	-8
Returns to Shareholders
Dividends	0	0	-0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2
Period End	3/31/2026	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023
Filing Date	5/15/2026	3/30/2026	11/13/2025	8/14/2025	5/14/2025	4/2/2025	11/12/2024	8/14/2024	5/14/2024	3/21/2024	11/29/2023	8/10/2023
Key Financials Quarterly
Total Revenue	1	1	0	0	0	0	0	0	0	0	0	0
Ebitda	-0	-1	-1	-1	-4	-2	-2	-4	-4	-5	-7	-6
Operating Income	-0	-1	-1	-1	-4	-2	-2	-4	-4	-5	-7	-6
Net Income	-0	-1	-1	-1	-0	-3	-2	-3	-3	-5	-6	-5
EPS	-0.04	-2.21	-1.31	-14.70	-0.23	-79.20	-43.80	-2582.70	-544.80	-1495.20	-115.20	-1576.80
Key Financials TTM
Total Revenue TTM	2	1	0	0	0	0	0	0	0	0	0	0
Ebitda TTM	-4	-8	-8	-10	-12	-12	-16	-20	-22	-25	-29	-29
Operating Income TTM	-4	-8	-8	-10	-12	-12	-16	-20	-22	-25	-29	-29
Net Income TTM	-3	-3	-5	-6	-8	-11	-13	-18	-20	-23	-25	-24
Growth Rates Quarterly
Total Revenue Growth	-	-	710.0%	-100.0%	-100.0%	-100.0%	-37.5%	-98.9%	-	-	-	-
EBITDA Growth	94.2%	42.8%	54.4%	63.8%	3.2%	64.8%	68.2%	38.5%	40.5%	39.4%	-5.9%	-2.5%
Operating Income Growth	94.2%	40.8%	54.4%	63.9%	3.2%	65.9%	68.2%	38.5%	40.5%	39.4%	-5.8%	-2.5%
Net Income Growth	-143.2%	80.0%	49.5%	59.5%	97.3%	42.1%	67.6%	40.2%	49.2%	29.0%	-18.4%	-19.1%
Margins Quarterly
EBITDA Margin	-31.5%	-161.9%	-1224.7%	-	-	-	-21760.0%	-90975.0%	-15010.3%	-17264.5%	-42737.5%	-1587.4%
Operating Income Margin	-31.6%	-162.5%	-1224.7%	-	-	-	-21770.0%	-91100.0%	-15017.2%	-17290.3%	-42781.2%	-1589.5%
Net Income Margin	-25.3%	-91.7%	-1219.8%	-	-	-	-19570.0%	-81425.0%	-10158.6%	-17003.2%	-37700.0%	-1460.6%
Cash & Debt
Total Cash	3	4	4	4	3	3	3	6	3	3	6	10
Total Debt	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt / (Cash)	-3	-4	-4	-4	-3	-3	-3	-6	-3	-3	-6	-10
Cash Flows Quarterly
FCF from Operations	-0	-0	-0	-1	-3	-1	-3	-3	-0	-4	-4	-1
Cash Flows TTM
FCF from Operations TTM	-2	-5	-6	-9	-11	-8	-11	-12	-10	-16	-17	-20
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-0.2%	-0.9%	-0.9%	-1.2%	-3.8%	-1.7%	-1.8%	-3.0%	-2.8%	-4.7%	-5.8%	-5.1%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-0.8%	-1.7%	-1.9%	-2.2%	-2.7%	-2.6%	-3.0%	-4.0%	-4.6%	-5.3%	-5.9%	-5.8%

Segment Financials

Revenue by Segment

$ Mil	2025	2024
Clinical trial supply	0
Fire safety equipment	0
Maintenance & Servicing	0
Project - supply & installation	0
Safety aparel	0
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and		0
Total	0	0

Operating Income by Segment

$ Mil	2025	2024	2023	2022	2021
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and		-25
Total		-25

Net Income by Segment

$ Mil	2025	2024	2023	2022	2021
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and		-23
Total		-23

Assets by Segment

$ Mil	2025	2024	2023	2022	2021
Development of innovative cancer medicines based on cell cycle, transcriptional regulation and			28	43	46
Total			28	43	46

	1M	2M	3M	6M	1Y	3Y
Beta	0.36	0.79	2.26	2.26	-0.34	0.32
Up Beta	-0.72	-0.35	2.73	3.02	2.09	-0.60
Down Beta	14.89	-1.42	-0.17	2.71	0.19	0.02
Up Capture	76%	175%	227%	90%	-11%	-1%
Bmk +ve Days	15	22	31	66	141	428
Stock +ve Days	12	22	27	52	63	63
Down Capture	713%	206%	272%	203%	173%	89%
Bmk -ve Days	4	18	30	56	108	321
Stock -ve Days	7	16	31	66	87	87

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with BGMS
BGMS	-81.3%	113.4%	-1.61	-
Sector ETF (XLV)	12.0%	14.7%	0.55	5.5%
Equity (SPY)	26.8%	12.1%	1.67	23.1%
Gold (GLD)	37.5%	26.8%	1.16	2.1%
Commodities (DBC)	43.5%	18.6%	1.80	0.4%
Real Estate (VNQ)	12.0%	13.4%	0.59	13.0%
Bitcoin (BTCUSD)	-27.2%	41.8%	-0.65	32.8%

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with BGMS
BGMS	-28.4%	113.4%	-1.61	-
Sector ETF (XLV)	5.4%	14.6%	0.19	5.5%
Equity (SPY)	13.8%	17.0%	0.64	23.1%
Gold (GLD)	19.3%	18.0%	0.87	2.1%
Commodities (DBC)	10.8%	19.4%	0.44	0.4%
Real Estate (VNQ)	3.8%	18.8%	0.10	13.0%
Bitcoin (BTCUSD)	9.3%	55.6%	0.37	32.8%

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with BGMS
BGMS	-15.4%	113.4%	-1.61	-
Sector ETF (XLV)	9.8%	16.5%	0.48	5.5%
Equity (SPY)	15.5%	17.9%	0.74	23.1%
Gold (GLD)	13.2%	16.0%	0.68	2.1%
Commodities (DBC)	7.8%	17.9%	0.35	0.4%
Real Estate (VNQ)	5.4%	20.7%	0.22	13.0%
Bitcoin (BTCUSD)	67.3%	66.9%	1.06	32.8%

Short Interest

Short Interest: As Of Date	4302026
Short Interest: Shares Quantity	0.0 Mil
Short Interest: % Change Since 4152026	-38.3%
Average Daily Volume	0.1 Mil
Days-to-Cover Short Interest	1
Basic Shares Quantity	5.5 Mil
Short % of Basic Shares	0.7%

Returns Analyses

	Title
0	Can Bio Green Med Solution Stock Hold Up When Markets Turn?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
3/30/2026	3.8%	9.0%	-3.0%
11/13/2025	-2.2%	-8.2%	0.0%
SUMMARY STATS
# Positive	1	1	1
# Negative	1	1	1
Median Positive	3.8%	9.0%	0.0%
Median Negative	-2.2%	-8.2%	-3.0%
Max Positive	3.8%	9.0%	0.0%
Max Negative	-2.2%	-8.2%	-3.0%

	Forward Returns
3/30/2026	3.8%	9.0%	-3.0%
11/13/2025	-2.2%	-8.2%	0.0%
SUMMARY STATS
# Positive	1	1	1
# Negative	1	1	1
Median Positive	3.8%	9.0%	0.0%
Median Negative	-2.2%	-8.2%	-3.0%
Max Positive	3.8%	9.0%	0.0%
Max Negative	-2.2%	-8.2%	-3.0%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
03/31/2026	05/15/2026	10-Q
12/31/2025	03/30/2026	10-K
09/30/2025	11/13/2025	10-Q
06/30/2025	08/14/2025	10-Q
03/31/2025	05/14/2025	10-Q
12/31/2024	04/02/2025	10-K
09/30/2024	11/12/2024	10-Q
06/30/2024	08/14/2024	10-Q
03/31/2024	05/14/2024	10-Q
12/31/2023	03/21/2024	10-K
09/30/2023	11/29/2023	10-Q
06/30/2023	08/10/2023	10-Q
03/31/2023	05/11/2023	10-Q
12/31/2022	03/08/2023	10-K
09/30/2022	11/10/2022	10-Q
06/30/2022	08/11/2022	10-Q

Recent Forward Guidance [BETA]

Latest: Q1 2026 Earnings Reported 5/14/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
Q4 2026 Cash Runway

Prior: Q3 2025 Earnings Reported 11/13/2025

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
Q1 2026 Cash Runway

Insider Activity

Expand for More

#	Owner	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Yap, Kim Choy	Direct	Sell	11052025	1.70	28,540			Form
2	Yap, Kim Choy	Direct	Sell	11032025	1.81	112,260	202,854	51,500	Form
3	Kua, Khai Loon	Direct	Sell	11032025	1.80	242,477			Form
4	Ong, Yee Lung	Direct	Sell	11032025	1.80	248,814			Form
5	Yap, Kim Choy	Direct	Sell	10312025	1.83	110,749	203,114	258,154	Form

BGMS Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

Looking for high-conviction positions with a better risk/reward profile? See what's currently in the Trefis High Quality Portfolio.

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing BGMS?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What BGMS Makes & Who Pays

TTM figures based on

BGMS Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Bio Green Med Solution (BGMS)

Market Price (5/22/2026): $1.02 | Market Cap: $5.6 MilSector: Health Care | Industry: Biotechnology

Bio Green Med Solution (BGMS)

Market Price (5/22/2026): $1.02Market Cap: $5.6 MilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About Bio Green Med Solution (BGMS)

Capital Allocation Decisions (Bio Green Med Solution, Inc. - BGMS)

Share Issuance

Inbound Investments

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets vs. Bio Green Med Solution (BGMS)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance [BETA]

Insider Activity

BGMS Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

Market Price (5/22/2026): $1.02 | Market Cap: $5.6 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (5/22/2026): $1.02
Market Cap: $5.6 Mil
Sector: Health Care
Industry: Biotechnology